Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 15, 2017 (9 years ago)

Fosphenytoin Sodium Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of particulate matter

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Fosphenytoin Sodium Injection, USP 500 mg PE*/10 mL, Made in India. Distributed by: Amneal Biosciences, Bridgewater, NJ 08807, NDC 70121-1390-1

Affected NDC 70121-1390-01

Compare with the code on your package — it is the most precise check available.

Drug: Phenytoin

Recalling firm
Amneal Pharmaceuticals
NDC code
70121-1390-1
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0610-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phenytoin recalls

See all
Class I · High risk

Phenytoin Oral Suspension

Failed Content Uniformity Specifications

Terminated Wrong potency / content The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7079-24 D-0153-2024
Class II · Moderate risk

Extended Phenytoin Sodium Capsules

Failed Dissolution Specifications: Out-of-specification results for dissolution (above specification)

Terminated Dissolution failure Amneal Pharmaceuticals of New York, LLC NDC 65162-212-10 D-0876-2023
Class III · Low risk

Phenytoin Sodium Injection

Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.

Terminated Labeling / mix-up Acella Pharmaceuticals, LLC NDC 42192-614-05 D-0070-2023
Class III · Low risk

Phenytoin Sodium Injection

Labeling: Not elsewhere classified; the product is being recalled because of customer complaints that the primary vial label was missing a barcode.

Terminated Labeling / mix-up Acella Pharmaceuticals, LLC NDC 42192-614-02 D-0069-2023

Other recalls by Amneal Pharmaceuticals

All 2017 recalls
Class III · Low risk

Primidone Tablets

Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.

Ongoing Cross-contamination Amneal Pharmaceuticals, LLC D-0585-2026
Class II · Moderate risk

traMADol Hydrochloride Tablets

Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).

Ongoing Nitrosamine impurity Amneal Pharmaceuticals, LLC NDC 60219-2348-5 D-0408-2026
Class I · High risk

Magnesium Sulfate in Water for Injection

Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.

Ongoing Labeling / mix-up Amneal Pharmaceuticals, LLC NDC 70121-1720-3 D-0478-2026
Class II · Moderate risk

chlorproMAZINE Hydrochloride Tablets

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Ongoing Particulate / foreign matter Amneal Pharmaceuticals, LLC NDC 69238-1062-1 D-0619-2025